Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
This study is ongoing, but not recruiting participants.
Study NCT00036790 Information provided by National Cancer Institute (NCI)
First Received: May 13, 2002 Last Updated: November 16, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Leukemia
Lung Cancer
Lymphoma
Prostate Cancer
Small Intestine Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Colorectal Neoplasms
Duodenal Neoplasms
Head and Neck Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Lung Neoplasms
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Multiple Myeloma
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms, Plasma Cell
Prostatic Neoplasms
More general conditions related to this trial
Blood Protein Disorders
Bone Marrow Diseases
Breast Diseases
Cardiovascular Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lung Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Paraproteinemias
Prostatic Diseases
Rectal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Vascular Diseases
Interventions listed in this trial
doxorubicin hydrochloride
motexafin gadolinium
Additional drug interventions recognized in this trial
Doxorubicin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Dermatologic Agents
Pharmacologic Actions
Photosensitizing Agents
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Wisconsin, Madison
National Cancer Institute (NCI)
Back to top of Main Content
